Skip to main content

2021 to 2023 Saw Considerable Increase in Semaglutide Fills

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 5, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Aug. 5, 2024 -- From 2021 through 2023, there was a considerable increase in the number of semaglutide fills, according to a research letter published online Aug. 2 in JAMA Health Forum.

Christopher Scannell, M.D., Ph.D., from the University of Southern California in Los Angeles, and colleagues analyzed trends in prescriptions dispensed at retail pharmacies for semaglutide between January 2021 and December 2023. Monthly fills were calculated for semaglutide by drug brand (Ozempic, Wegovy, and Rybelsus) and payment method.

The researchers observed a 442 percent increase in the number of semaglutide fills between January 2021 and December 2023; Ozempic accounted for more than 70 percent of these fills. Increases were seen for all three drug brands, with variation in the extent and timing of these increases. Ozempic increased 392 percent between January 2021 and December 2023, peaking in August 2023 before reaching a plateau; notable increases in Wegovy fills started in January 2023, peaked in May 2023, then plateaued, with an increase of more than 1,361 percent seen between July 2021 and December 2023. For all three drug brands, increases in monthly semaglutide fills were seen across all payment methods between 2021 and 2023, with most fills accounted for by prescriptions paid through commercial insurance.

"The number of prescriptions filled for semaglutide has increased substantially, reaching 2.6 million prescriptions filled at retail pharmacies by December 2023," the authors write. "Future research should examine how changes in Medicare Part D and Medicaid coverage restrictions influence disparities in access to these essential medications."

One author disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists

WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...

Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes

WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...

Adverse Pregnancy Outcomes Partly Mediate Association Between Prepregnancy Obesity, CVD Risk

MONDAY, April 21, 2025 -- Adverse pregnancy outcomes (APOs) mediate a small proportion of the association between prepregnancy obesity and cardiovascular disease (CVD) risk in...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.